サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1138319

リポソーマルドキソルビシンの世界市場-2022-2029

Global Liposomal Doxorubicin Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
リポソーマルドキソルビシンの世界市場-2022-2029
出版日: 2022年10月18日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

リポソーマルドキソルビシンの世界市場の成長は、世界のがんの有病率の上昇とドキソルビシンを製造する企業数の増加によって牽引されています。

世界のがん罹患率の上昇とドキソルビシンを製造する企業数の増加が

ドキソルビシンを製造する企業の増加が市場成長の原動力になると予想されます。

がん患者数の増加が、リポソーマルドキソルビシンの世界市場を牽引しています。例えば、世界保健機関（WHO）によると、毎年、世界の死因の13％はがんが占めています。さらに、今後数十年の間にがん罹患率が70%増加することが予想されており、世界の老年人口は2015年から2022年にかけて、12%から22%へとほぼ倍増することが予測されています。世界のすべての種類のがんの発生率は、2015年から2030年にかけてCAGR2.5％で増加すると予測されています。がんの死亡率は、2015-2030年の間にCAGR 2.6%で、発生率よりも高い割合で増加すると思われます。

また、メーカーによる製品開発の高まりや新規プレイヤーの市場参入により、予測期間中に市場成長が押し上げられると推測されます。例えば、2019年3月、Cytori Therapeutics, Inc.は、Doxorubicin Hydrochloride Cytoriの正式な新薬申請前申請を欧州医療機関（EMA）に提出しました。この申請は、EMAの集中承認手続きによる販売許可申請（MAA）のための第58条申請の前段階となるものです。

ドキソルビシンに関連する副作用が市場成長の妨げになると予想されます。

リポソーマルドキソルビシンに関連するいくつかの副作用があり、予測期間中の市場成長の妨げになると予想されています。副作用の一部には、感染症にかかるリスクの増加、息切れや顔色の悪さ、あざ、歯ぐきの出血、鼻血、治療中や治療後の疲れや脱力感（疲労）、手足の痛み、赤み、皮むき、食欲不振や体重減少、下痢や便秘等が挙げられます。

産業分析

リポソーマルドキソルビシンの世界市場は、ポーターのファイブフォース分析、疫学、規制分析、サプライチェーン分析、製品の革新、アンメットニーズなどの様々な業界要因に基づいて、市場の詳細な分析を提供します。

世界のリポソーマルドキソルビシン市場レポートでは、約45+市場データ表、40+図、180ページへのアクセスを提供する予定です。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場影響要因
    • 促進要因
      • 世界のがん罹患率の上昇とドキソルビシンの製造企業数の増加
    • 抑制要因
      • ドキソルビシンに関連する副作用
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • 疫学
  • 規制分析
  • サプライチェーン分析
  • 製品イノベーション
  • アンメットニーズ

第6章 製品別

  • ドキシル/ケイレックス
  • リポドックス
  • ミオセット
  • その他

第7章 製剤別

  • 凍結乾燥粉末
  • ドキソルビシン注射液

第8章 用途別

  • カポジ肉腫
  • 白血病
  • 乳がん
  • 卵巣がん
  • 多発性骨髄腫
  • 子宮内膜がん
  • 肝臓がん
  • 骨肉腫
  • 腎臓がん
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第12章 企業プロファイル

  • Pfizer Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • SRS Pharmaceuticals Pvt. Ltd.
  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Cadila Pharmaceuticals
  • Merck & Co.
  • Cipla, Inc.

第13章 リポソーマルドキソルビシンの世界市場-DataM

目次
Product Code: DMPH2194

Market Overview

Liposomal doxorubicin Market size was valued US$ 1,160 million in 2022 and is estimated to reach US$ 2 billion by 2029, growing at a CAGR of 6.2 % during the forecast period (2022-2029).

Liposomal Doxorubicin is a chemotherapy drug-containing doxorubicin (Adriamycin) wrapped up in a fatty covering called a liposome. Doxorubicin blocks an enzyme called topoisomerase 2 that cancer cells need to divide and grow. Liposomal doxorubicin is doxorubicin contained in tiny spheres called pegylated liposomes. These spheres keep the doxorubicin in the bloodstream longer so that more of the drug reaches the cancer cells. It is used to treat several types of cancer, including breast cancer, ovarian cancer, Kaposi's sarcoma, and multiple myeloma.

Market Dynamics

The global liposomal doxorubicin market growth is driven by the surge in prevalence of cancer globally and Increasing number of companies manufacturing doxorubicin.

The rising prevalence of cancer globally and Increasing number of companies

manufacturing doxorubicin are expected to drive market growth.

The rising number of cancer cases drives the global liposomal doxorubicin market. For instance, according to the World Health Organization (WHO), cancer accounts for 13% of deaths globally every year. Moreover, a 70% increase in cancer incidences is anticipated over the next couple of decades, and the global geriatric population is anticipated to nearly double from 12% to 22%, from 2015 to 2022. The incidence of all cancer types worldwide is anticipated to increase at a CAGR of 2.5% during 2015-2030. The mortality rate of cancers is likely to increase at a higher rate than the incidence rate during 2015-2030, at a CAGR of 2.6%.

The market growth is also estimated to boost over the forecast period due to rising product development by manufacturers and new players entering the market. For instance, in March 2019, Cytori Therapeutics, Inc. has filed a formal new drug application pre-submission request to the European Medicine Agency (EMA) for Doxorubicin Hydrochloride Cytori. This submission is the precursor to filing an Article 58 Application for a Marketing Authorization Application (MAA) via EMA's centralized approval procedure.

Side Effects associated with doxorubicin is expected to hamper the market growth.

There are some side-effects associated with liposomal doxorubicin which are expected to hamper the market's growth over the forecast period. some of the side-effects include increased risk of getting an infection, breathlessness and looking pale, bruising, bleeding gums and nosebleeds, tiredness and weakness (fatigue) during and after treatment, soreness, redness and peeling of your hands and feet, loss of appetite and weight loss, diarrhea or constipation, among others.

Industry Analysis

The global liposomal doxorubicin market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces Analysis, Epidemiology, Regulatory Analysis, Supply Chain Analysis, Product Innovations, Unmet Needs.

Segment Analysis

Doxil/Caelyx segment is expected to hold the largest market share in global liposomal doxorubicin market

The market is segmented into Doxil/Caelyx, Lipodox, Myocet, and Others based on product type. Doxil/Caelyx segment accounted for the highest market share, owing to the rising incidence of ovarian and breast cancers. The increasing demand for Doxil or Caelyx (J&J) as a second-line treatment for ovarian carcinoma is also expected to boost its growth over the forecast period. Caelyx/Doxil is a novel pegylated liposomal formulation of the first-generation anthracycline, doxorubicin. The pharmacokinetics of this polyethylene-glycol-coated liposome is characterized by a reduced volume of distribution, a long intravascular circulating half-life and slow plasma clearance compared with free doxorubicin.

By application, the liposomal doxorubicin market is segmented into Kaposi sarcoma, leukemia, breast cancer, multiple myeloma, ovarian cancer, endometrial cancer, liver cancer, bone sarcoma, kidney cancer, and others. Among these, breast cancer accounted for the highest market share in 2018, owing to rising demand for the treatment in increasing breast cancer cases globally. According to Breastcancer.org, about 1 in 8 U.S. women (about 12%) develop invasive breast cancer over the course of their lifetime. In 2019, an estimated 268,600 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 62,930 new non-invasive (in situ) breast cancer cases. About 2,670 new cases of invasive breast cancer are expected to be diagnosed in men in 2019. A man's lifetime risk of breast cancer is about 1 in 883. According to the American Cancer Institute, Doxorubicin is used during advanced breast cancer treatment as a chemo drug. It is observed that 3 million women diagnosed with breast cancer are currently there in the United States. Hence, an increasing burden of breast cancer leads to a rise in demand for treatment.

Geographical Analysis

North America region holds the largest market share in the global liposomal doxorubicin market

North America is dominating the global liposomal doxorubicin market, accounting for the largest market share in 2018, owing to an increasing number of cancer cases and consequently growing demand for doxorubicin in mono and combination chemotherapies. United States is the biggest market share holder of liposomal doxorubicin development and it has been allowed to import the medicine under the exercise enforcement discretion. The huge demand of liposomal doxorubicin in the market is fueling the doxorubicin HCl liposome injections import. As of January 2019, more than 3.1 million women have a history of breast cancer in the U.S. Also, the growing number of partnerships, mergers and acquisitions for clinical trials with technologically advanced doxorubicin formulations drive the market's growth in this region.

Competitive Landscape

The liposomal doxorubicin market is highly competitive with the presence of a large number of major players. Some of the major players in the global liposomal doxorubicin market include Johnson & Johnson, SRS Pharmaceuticals Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Cadila Pharmaceuticals, Merck & Co., Cipla, Inc., Pfizer Inc., among others.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the growth of the liposomal doxorubicin market globally. For instance,

In January 2019, Celsion Corporation, an oncology drug development company, announced results from Phase I TARDOX trial of ThermoDox conducted at the University of Oxford, United Kingdom. The TARBOX trial evaluated the safety and efficacy of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, along with focused ultrasound for the treatment of liver cancer.

Key Companies to Watch

Pfizer Inc.

Overview: Pfizer Inc. is an American multinational pharmaceutical corporation that works in biotechnology domain also. It was founded in 1849 and headquartered in Manhattan, New York City. It is a manufacturer of various vaccines and medicines for cardiology, oncology, neurology, immunology.

Products Portfolio: NYVEPRIA: It is helpful in reducing the incidence of infection, caused by febrile neutropenia, to the patients that have non-myeloid malignancies and are getting myelosuppressive anti-cancer drugs related with a clinically notable increase of febrile neutropenia.

Key Developments: In Aug 2021, Trillium Therapeutics Inc was attained for around $2.3 billion by this company along with its immuno oncology portfolio.

The global liposomal doxorubicin market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Rising prevalence of cancer globally and Increasing number of companies manufacturing doxorubicin
    • 4.1.2. Restraints:
      • 4.1.2.1. Side Effects associated with Doxorubicin
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Epidemiology
  • 5.3 Regulatory Analysis
  • 5.4 Supply Chain Analysis
  • 5.5 Product Innovations
  • 5.6 Unmet Needs

6. By Product

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product Segment
  • 6.2. Doxil/Caelyx
      • 6.2.1.1. Introduction
      • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 6.3. Lipodox
  • 6.4. Myocet
  • 6.5. Others

7. By Drug Formulation

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 7.1.2. Market Attractiveness Index, By Drug Formulation Segment
  • 7.2. Lyophilized Powder
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Doxorubicin Injection

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Kaposi Sarcoma
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Leukemia
  • 8.4. Breast Cancer
  • 8.5. Ovarian cancer
  • 8.6. Multiple Myeloma
  • 8.7. Endometrial Cancer
  • 8.8. Liver Cancer
  • 8.9. Bone Sarcoma
  • 8.10. Kidney Cancer
  • 8.11. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1 Pfizer Inc.
    • 12.1.1 Company Overview
    • 12.1.2 Product Portfolio and Description
    • 12.1.3 Key Highlights
    • 12.1.4 Financial Overview
  • 12.2 SRS Pharmaceuticals Pvt. Ltd.
  • 12.3 Johnson & Johnson
  • 12.4 Sun Pharmaceutical Industries Ltd.
  • 12.5 Cadila Pharmaceuticals
  • 12.6 Merck & Co.
  • 12.7 Cipla, Inc.

LIST NOT EXHAUSTIVE

13. Global Liposomal Doxorubicin Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Distribution Channel
  • 13.3. Contact Us